Login to Your Account

Acelrx's FDA Zalviso verdict due, may face-off with Ionsys

By Randy Osborne
Staff Writer

Tuesday, August 4, 2015

Running another trial with the pain drug Zalviso "to us, just doesn't make sense," Timothy Morris, chief financial officer of Acelrx Pharmaceuticals Inc., told BioWorld Today, and the company will find out next month how flexible the FDA might be.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription